Business Description
Pulmonx Corp
NAICS : 334510
SIC : 3842
ISIN : US7458481014
Share Class Description:
LUNG: Ordinary SharesTotal Employee Number:
296Description
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.09 | |||||
Equity-to-Asset | 0.38 | |||||
Debt-to-Equity | 1.23 | |||||
Debt-to-EBITDA | -1.17 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -5.65 | |||||
Beneish M-Score | -3.4 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 15.4 | |||||
3-Year EBITDA Growth Rate | 7.1 | |||||
3-Year EPS without NRI Growth Rate | 5.8 | |||||
3-Year FCF Growth Rate | 13.6 | |||||
3-Year Book Growth Rate | -31.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 15.3 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 6.71 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 56.44 | |||||
9-Day RSI | 52.84 | |||||
14-Day RSI | 50.96 | |||||
3-1 Month Momentum % | 21.05 | |||||
6-1 Month Momentum % | -30 | |||||
12-1 Month Momentum % | -40.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.91 | |||||
Quick Ratio | 4.04 | |||||
Cash Ratio | 3.26 | |||||
Days Inventory | 273.74 | |||||
Days Sales Outstanding | 54.89 | |||||
Days Payable | 82.86 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.5 | |||||
Shareholder Yield % | -0.27 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 75.49 | |||||
Operating Margin % | -58.79 | |||||
Net Margin % | -60.09 | |||||
EBITDA Margin % | -54.46 | |||||
FCF Margin % | -33.22 | |||||
OCF Margin % | -33.04 | |||||
ROE % | -86.75 | |||||
ROA % | -38.81 | |||||
ROIC % | -114.42 | |||||
3-Year ROIIC % | 260.83 | |||||
ROC (Joel Greenblatt) % | -141.07 | |||||
ROCE % | -42.71 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.65 | |||||
PB Ratio | 1.28 | |||||
Price-to-Tangible-Book | 1.35 | |||||
EV-to-EBIT | -1.09 | |||||
EV-to-EBITDA | -1.11 | |||||
EV-to-Revenue | 0.6 | |||||
EV-to-Forward-Revenue | 0.59 | |||||
EV-to-FCF | -1.82 | |||||
Price-to-GF-Value | 0.19 | |||||
| Price-to-Net-Current-Asset-Value | 3.16 | |||||
Earnings Yield (Greenblatt) % | -91.74 | |||||
FCF Yield % | -50.1 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:LUNG
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pulmonx Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 88.545 | ||
| EPS (TTM) ($) | -1.3 | ||
| Beta | 0.9422 | ||
| 3-Year Sharpe Ratio | -0.78 | ||
| 3-Year Sortino Ratio | -1.01 | ||
| Volatility % | 76.13 | ||
| 14-Day RSI | 50.96 | ||
| 14-Day ATR ($) | 0.120161 | ||
| 20-Day SMA ($) | 1.369 | ||
| 12-1 Month Momentum % | -40.81 | ||
| 52-Week Range ($) | 1.13 - 3.88 | ||
| Shares Outstanding (Mil) | 42.24 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pulmonx Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pulmonx Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-12 16:30 | In 130 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 129 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-30 16:30 | In 25 days | ||
| Second quarter earnings results for 2026 | 2026-07-30 | In 24 days | ||
| General meeting for 2026 | 2026-06-04 08:00 | 1.52 (-3.80%) | ||
| Guidance call for 2026 | 2026-05-12 08:15 | 1.30 (+3.17%) | ||
| First quarter earnings conference call for 2026 | 2026-04-29 16:30 | 1.23 (-3.91%) | ||
| First quarter earnings results for 2026 | 2026-04-29 | 1.23 (-3.91%) | ||
| Annual report for 2025 | 2026-03-10 | 1.82 (-5.70%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-04 16:30 | 1.53 (+2.00%) |
Show
Entries
Pulmonx Corp Frequently Asked Questions
What is Pulmonx Corp(LUNG)'s stock price today?
The current price of LUNG is $1.39. The 52 week high of LUNG is $3.88 and 52 week low is $1.13.
When is next earnings date of Pulmonx Corp(LUNG)?
The next earnings date of Pulmonx Corp(LUNG) is 2026-07-30 Est..
Does Pulmonx Corp(LUNG) pay dividends? If so, how much?
Pulmonx Corp(LUNG) does not pay dividend.
Guru Commentaries on NAS:LUNG
No articles.
Press Release
Articles on Pulmonx Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers